Evidence map›Paper›PMID 39555704›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Precise HER2 Protein Degradation via Peptide-Conjugated Photodynamic Therapy for Enhanced Breast Cancer Immunotherapy.

Changyong Guo, Fei Gao, Guoyuan Wu, Jinqiu Li, Chunquan Sheng, Shipeng He, Honggang Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. A Plug-and-Play Platform for Customizing Multivalent Degraders and Degrader-Drug Conjugates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Emerging Nanozyme Strategies for Precision Breast Cancer Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Changyong GuoSchool of Medicine or Institute of Translational Medicine, Shanghai Engineering Research Center of Organ Repair, Shanghai University, 99 Shangda Road, Shanghai, 200444, P. R. China.
Fei GaoSchool of Medicine or Institute of Translational Medicine, Shanghai Engineering Research Center of Organ Repair, Shanghai University, 99 Shangda Road, Shanghai, 200444, P. R. China.
Guoyuan WuSchool of Medicine or Institute of Translational Medicine, Shanghai Engineering Research Center of Organ Repair, Shanghai University, 99 Shangda Road, Shanghai, 200444, P. R. China.
Jinqiu LiSchool of Medicine or Institute of Translational Medicine, Shanghai Engineering Research Center of Organ Repair, Shanghai University, 99 Shangda Road, Shanghai, 200444, P. R. China.
Chunquan ShengThe Center for Basic Research and Innovation of Medicine and Pharmacy (MOE), School of Pharmacy, Second Military Medical University (Naval Medical University), 325 Guohe Road, Shanghai, 200433, P. R. China.
Shipeng HeSchool of Medicine or Institute of Translational Medicine, Shanghai Engineering Research Center of Organ Repair, Shanghai University, 99 Shangda Road, Shanghai, 200444, P. R. China.ORCID 0000-0001-6673-5956
Honggang HuSchool of Medicine or Institute of Translational Medicine, Shanghai Engineering Research Center of Organ Repair, Shanghai University, 99 Shangda Road, Shanghai, 200444, P. R. China.

Funding

Key Technologies Research and Development Program 2021YFC2100201National Natural Science Foundation of China 22077078National Natural Science Foundation of China 82373707Science Fund for Distinguished Young Scholars of Fujian Province 2024J010045Shanghai Rising-Star Program 23QA1403500
6 · The paper itself

Abstract

Breast cancer, the most prevalent malignancy among women, frequently exhibits high HER2 expression, making HER2 a critical therapeutic target. Traditional treatments combining the anti-HER2 antibody trastuzumab with immunotherapy face limitations due to toxicity and tumor microenvironment immunosuppression. This study introduces an innovative strategy combining HER2-targeting peptides with the photosensitizer (PSs) pyropheophorbide-a (Pha) via a gelatinase-cleavable linker, forming self-assembling nanoparticles. These nanoparticles actively target breast cancer cells and generate reactive oxygen species (ROS) under near-infrared light, effectively degrading HER2 proteins. Upon internalization, the linker is cleaved, releasing Pha-PLG and enhancing intracellular photodynamic therapy (PDT). The Pha-PLG molecules self-assemble into nanofibers, prolonging circulation, boosting immune induction, and activating CD8

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunotherapyPeptidesPhotochemotherapyAnimalsCell Line, TumorChlorophyllFemaleHumansMiceMice, Inbred BALB CNanoparticlesPhotosensitizing AgentsReactive Oxygen SpeciesChlorophyllERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPeptidesPhotosensitizing Agentspyropheophorbide aReactive Oxygen Speciesbreast cancergelatinase responsive peptidesimmune inductionphoto‐controlled her2 protein degradationphotodynamic immunotherapy

Identifiers

PMID39555704
PMCPMC11727380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.